Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of July 2026
Date of Filing: July 6, 2026
The registrant is a biopharmaceutical company based in Ramat Gan, Israel. This filing incorporates by reference the first four paragraphs of a press release issued on July 6, 2026, regarding a clinical trial milestone.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K is a current report focused on a specific corporate event rather than a periodic financial statement.
Material Changes and Clinical Milestones
- Event: Completion of patient enrollment for the interim analysis of a pivotal Phase 3 clinical trial for psoriasis.
- Significance: This is described as a key milestone in the company's development pipeline.
- Data Expectation: Data from the interim analysis is expected to be available in Q4 2026 or Q1 2027.
Guidance, Outlook, and Risks
Outlook: Management anticipates the release of interim analysis data in the latter half of 2026 or early 2027. No specific financial guidance or revenue projections are included in this filing.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the inherent uncertainties of clinical trial outcomes. The success of the interim analysis remains pending.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed trial design and statistical endpoints.
- Monitor upcoming announcements for the release of interim data in Q4 2026/Q1 2027.
- Review the company's most recent Form 20-F for current cash runway and burn rate, as this filing contains no financial data.
- Confirm the regulatory status of the psoriasis indication with relevant health authorities.